Hera Biotech

Hera Biotech is a private, pre-revenue diagnostics company founded in 2018, pioneering non-invasive solutions for chronic gynecologic conditions. Its core platform consists of two main products: MetriDx™, a molecular test for endometriosis, and HERAfem™, a point-of-care device for cervical lesion detection. The company is addressing a significant market gap characterized by long diagnostic delays, high misdiagnosis rates, and invasive current standards, with initial commercial launches for HERAfem planned for Latin America in 2026. Backed by a team with strong life science exit experience and clinician investors, Hera is positioning itself to set a new diagnostic standard in women's health.

Proprietary AI-powered molecular imaging and data analytics platform for non-invasive, tissue-based diagnostics. Built on a foundation of 20B+ data points and proprietary datasets.

The competitive landscape includes companies developing non-invasive biomarker tests for endometriosis (e.g., DotLab, Ziwig) and established players in cervical cancer screening (Pap smear, HPV testing, colposcopy). Hera differentiates by combining a tissue-based, AI-powered platform targeting both conditions with a specific focus on point-of-care deployment in resource-varied settings.